DUBLIN–(BUSINESS WIRE)–The “North America Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027” report has been added to ResearchAndMarkets.com’s offering.
The North America Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of 5.6% CAGR during the forecast period.
While it’s difficult to define who develops IPF, some studies showcase that more males are diagnosed with the disease than females. Age is also a determining factor in IPF. In a vast number of researches, older age has been identified as a prevalent diagnostic factor for IPF.
According to the Centers for Disease Control and Prevention, more than 14% (34.1 million) of adults in the United States smoked tobacco in 2019. As per the American IPF Foundation, the incidence of idiopathic pulmonary fibrosis (IPF) has doubled in the last ten years. In the United States, an estimated 50,000 people die from IPF each year, which is higher than breast cancer.
Moreover, the Centers for Disease Control and Prevention recently discovered a statistically significant cluster of IPF patients diagnosed at a Virginia medical centre. Because of the increased frequency of the condition, as well as the rising geriatric population and smoking habits, the United States is a prominent country of the regional market. In the United States, idiopathic pulmonary fibrosis treatment costs $100,000 per year, according to data published in the American Journal of Managed Care (AJMC) in 2014.
The US market dominated the North America Idiopathic Pulmonary Fibrosis Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $1,269.5 million by 2027. The Canada market is poised to grow at a CAGR of 8% during (2021 – 2027). Additionally, The Mexico market is expected to display a CAGR of 7% during (2021 – 2027).
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Pirfenidone
- Nintedanib
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country: US, Canada, Mexico, and Rest of North America.
Key Market Players
- GNI Group Ltd.
- Shionogi & Co., Ltd.
- Mission Therapeutics Ltd.
- Galapagos NV
- FibroGen, Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Biogen, Inc.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis – Global
Chapter 4. North America Idiopathic Pulmonary Fibrosis Market by Drug Type
Chapter 5. North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel
Chapter 6. North America Idiopathic Pulmonary Fibrosis Market by Country
Chapter 7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/2ujc9s
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
